ZYME

#1712
Zymeworks Inc. - Common Stock
25.1 3 USD
-1.37%
Сектор: Здравоохранение
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
25.13
25.13
Годовой диапазон
16.00
29.75
Дневное изменение
-1.37%
Месячное изменение
-10.17%
6-месячное изменение
-5.03%
Годовое изменение
+41.66%
Предыдущее закрытие
25.4 8
Open
25.1 3
Low
25.1 3
High
25.1 3
Volume
112
Открыть полный график Full chart

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 1.84 B
  • Employee 264
  • Founded 2003
  • CEO Kenneth Galbraith
  • Website www.zymeworks.com
  • Headquarter Delaware, United States
  • FIGI BBG019XSYC89
  • Industry Биотехнологии
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-18.28
Коэффициент цена/денежный поток
23.63

Zymeworks Inc. - Common Stock

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange. In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics.

Новости